What are the side effects of Melanotan-II, and does it raise melanoma risk?

The short answer

Melanotan-II (MT-II) is an unapproved synthetic hormone analog injected for tanning — and its most serious concern is skin cancer. It darkens and changes existing moles, can trigger new and dysplastic (atypical) moles, and case reports document melanoma developing from moles during or shortly after use. Common side effects include nausea, facial flushing, spontaneous erections, and appetite loss; rare severe cases include rhabdomyolysis and priapism. Any changing mole warrants a dermatologist — urgently.

Evidence tier: Tier 1–2 for the documented dermatological and systemic harms; Tier 2 for the melanoma-causation question (case reports, not proof of causation). Educational content, not medical advice.

The key points:

• The big concern is moles and melanoma — MT-II darkens/changes moles and is linked to melanoma cases
• It's unapproved and gray-market — regulators actively warn against it
• Common side effects: nausea, flushing, spontaneous erections, appetite loss
• A changing mole is a red flag — see a dermatologist promptly

For the closely-related approved cousin, see Melanotan-II vs PT-141.

What is Melanotan-II?

Evidence tier: 2 — established pharmacology.

Melanotan-II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors. Through the MC1R receptor it stimulates melanocytes to produce melanin, darkening the skin — a tan without UV — and through MC4R it also suppresses appetite and can cause spontaneous erections (its MC4R-selective relative, bremelanotide/PT-141, is used for that effect). It's injected subcutaneously and is popular as an "injectable tan."

The crucial fact: Melanotan-II is not approved by any regulatory agency for any use. It was originally researched at the University of Arizona, but was never developed into an approved drug; the only α-MSH analog approved for medical use is afamelanotide (Scenesse), for a rare light-sensitivity disorder — not for cosmetic tanning. So all MT-II is unlicensed, gray-market product of unknown purity, and health regulators including Australia's TGA and the UK's MHRA have explicitly warned consumers against using it. That regulatory stance isn't bureaucratic caution — it reflects real documented harms, the most serious of which involves moles and skin cancer.

Does Melanotan-II cause melanoma or change moles?

Evidence tier: 1–2 — documented melanocytic changes; melanoma via case reports.

This is the most important part, and the honest answer is serious. MT-II directly stimulates the pigment cells (melanocytes) that also give rise to moles and melanoma — and the dermatology literature has documented exactly what you'd fear from that. A review of the risks of unregulated α-MSH analog use compiled reports of darkening of existing moles, the rapid appearance of new moles (including dysplastic/atypical nevi), and changes in the size and shape of existing melanocytic lesions (Habbema et al. 2017). Multiple case reports describe melanoma developing from a pre-existing mole during or shortly after Melanotan use — for example, a woman whose abdominal mole enlarged and changed color over three months after MT-II injections and proved to be melanoma (Paurobally et al. 2011), and eruptive atypical moles reported in others, including a case in a teenager with familial atypical mole syndrome (FAMMM case).

Two things make this dangerous, and both matter. First, MT-II may promote melanocytic activity and atypical mole formation — a plausible mechanism for cancer concern, even if case reports can't prove causation on their own. Second, and just as important, by darkening and changing moles it corrupts the exact signals used to catch melanoma early: the "is this mole changing color, size, or shape?" warning system that dermatologists rely on gets triggered by the drug itself, making genuine melanoma harder to spot and easier to dismiss. So MT-II is a double hit — a possible driver of melanocytic change, and a saboteur of early detection. Anyone with many moles, atypical/dysplastic nevi, a personal or family history of melanoma, or a syndrome like FAMMM is at particularly elevated concern.

What are the other side effects?

Evidence tier: 1–2 — reported across cases and studies.

Beyond the skin-cancer concern, MT-II has a notable side-effect profile. The common effects — reported consistently — include nausea (especially with initial doses), facial flushing and peripheral vasodilation, yawning, spontaneous penile erections, and appetite suppression. Many users also get generalized darkening of skin, new freckles, and darkening of the lips, gums, or other areas beyond where they wanted a tan. These are usually not dangerous but are frequent enough that they're part of the ordinary MT-II experience.

The rare but serious end is worth knowing. There are documented cases of systemic toxicity including rhabdomyolysis (muscle breakdown) and renal dysfunction after MT-II — one case in a man who injected six times the typical starting dose (Nelson & Bryant 2012, systemic toxicity/rhabdomyolysis) — and cases of priapism (a prolonged, painful erection that's a urologic emergency and can cause lasting erectile dysfunction). Because MT-II is gray-market, dosing is imprecise and purity uncertain, which raises the odds of overdose-type reactions. So the risk picture spans frequent nuisance effects, the central melanoma concern, and occasional severe events.

Who should absolutely avoid Melanotan-II?

Evidence tier: 2 — reasoned from the mechanism and cases.

Given the melanocyte-stimulating mechanism, certain people carry clearly elevated risk and should not use MT-II. That includes anyone with a personal or family history of melanoma or skin cancer, many moles or atypical/dysplastic nevi, familial atypical multiple mole melanoma (FAMMM) syndrome, or fair skin that burns easily — exactly the groups already at higher baseline melanoma risk, in whom stimulating melanocytes and masking mole changes is the worst combination. Realistically, because MT-II is unapproved, unstudied for safety, and linked to skin cancer, there's no group for whom a strong case exists — but these are the people for whom it's most clearly a bad idea.

For anyone who has used or is using MT-II, the essential action is dermatologic surveillance: get a skin/mole check, and watch existing moles for the ABCDE warning signs — Asymmetry, Border irregularity, Color variation, Diameter growth, and Evolution (any change over time). Because MT-II can itself change moles, the threshold to get a mole professionally evaluated should be low. This isn't fear-mongering; it's the standard melanoma-vigilance every dermatologist would advise for someone deliberately stimulating their melanocytes.

What should you do?

Evidence tier: 2 — practical safety.

The bottom line for anyone weighing MT-II: the cosmetic upside — a tan — is not worth introducing a drug that darkens your moles, may promote atypical melanocytic changes, is linked in case reports to melanoma, and undermines the very early-warning signs that catch skin cancer while it's curable. If a tan is the goal, the dermatology consensus favors sunless self-tanners (DHA-based) that color the skin's surface without touching melanocytes and carry none of this risk. And MT-II's gray-market status adds the usual purity, dosing, and contamination unknowns of any unregulated injectable (spotting counterfeit peptides).

If you are using MT-II or have, the priority is simple: see a dermatologist, get your moles checked, and get any changing mole evaluated promptly — don't assume a darkening or growing mole is "just the Melanotan." A changing mole can be melanoma, and melanoma caught early is highly treatable while melanoma caught late is not. That single behavior — taking mole changes seriously and acting on them — is the most important thing anyone touching this drug can do.

Limitations

This is educational content, not medical advice.

• Case reports link MT-II to melanoma but can't prove causation — the association and mechanism are concerning enough to act on regardless.
• MT-II darkens and changes moles, which both raises concern and masks melanoma warning signs.
• It's unapproved and gray-market — regulators warn against it; purity and dosing are uncertain.
• Rare serious harms (rhabdomyolysis, renal injury, priapism) are documented, often with higher doses.
• A changing mole warrants prompt dermatologist evaluation — do not dismiss it as a tanning effect.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Melanotan-II is an unapproved, gray-market tanning injection whose most serious problem is skin cancer: it stimulates the same pigment cells that form moles and melanoma, it darkens and changes existing moles, it's been linked in case reports to melanoma arising from moles, and — critically — it corrupts the mole-change warning signs used to catch melanoma early. On top of that it commonly causes nausea, flushing, spontaneous erections, and appetite loss, with rare severe cases of rhabdomyolysis and priapism, and regulators warn against it. The cosmetic benefit doesn't justify those risks; DHA self-tanners achieve a tan without touching melanocytes. If you use or have used MT-II, the essential step is dermatologic mole surveillance and prompt evaluation of any changing mole — because that's what catches melanoma while it's still curable.

Related on this site

• Melanotan-II vs PT-141: safety-first comparison
• Peptide injection-site discoloration
• PT-141 protocol guide
• Spotting counterfeit peptides
• Our evidence-tier framework

References

• Habbema L, Halk AB, Neumann M, Bergman W. 2017. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. PMID 28266027 — mole darkening, dysplastic nevi, melanoma case reports.
• Paurobally D, Jason F, Dezfoulian B, Nikkels AF. 2011. Melanotan-associated melanoma. Br J Dermatol 164(6):1403–1405. doi:10.1111/j.1365-2133.2011.10273.x — melanoma from a mole after MT-II.
• Nelson ME, Bryant SM, et al. 2012. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. PMID 23121206 — rhabdomyolysis and renal dysfunction.
• Changes of melanocytic lesions induced by Melanotan injections and sunbed use in a teenage patient with FAMMM syndrome. PMC3663356 — melanocytic changes in a high-risk patient.